Published in Biometrics on September 01, 1993
State-of-the-science workshop report: issues and approaches in low-dose-response extrapolation for environmental health risk assessment. Environ Health Perspect (2008) 1.77
Risk assessment of thyroid follicular cell tumors. Environ Health Perspect (1998) 0.95
Statistical issues in the analysis of low-dose endocrine disruptor data. Toxicol Sci (2001) 2.27
Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics (1988) 2.26
Risk from low-dose exposures. Science (1994) 1.99
Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam Appl Toxicol (1989) 1.79
Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol Appl Pharmacol (1997) 1.75
Lung dosimetry and risk assessment of nanoparticles: evaluating and extending current models in rats and humans. Inhal Toxicol (2006) 1.65
Human exposure estimates for phthalates. Environ Health Perspect (2000) 1.53
Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol (1999) 1.43
Diversity of trends in occupational injury mortality in the United States, 1980-96. Inj Prev (2003) 1.34
Comparison of unintentional fatal occupational injuries in the Republic of Korea and the United States. Inj Prev (2004) 1.30
Sources of uncertainty in dose-response modeling of epidemiological data for cancer risk assessment. Ann N Y Acad Sci (1999) 1.21
Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments. Cancer Res (1986) 1.18
Temperature and air pollution as risk factors for heat stroke in Tokyo, July and August 1980-1995. Environ Health Perspect (1999) 1.18
Deindustrialisation and the long term decline in fatal occupational injuries. Occup Environ Med (2004) 1.15
Effects of temperature and air pollutants on cardiovascular and respiratory diseases for males and females older than 65 years of age in Tokyo, July and August 1980-1995. Environ Health Perspect (2001) 1.08
Receptor mechanisms and dose-response models for the effects of dioxins. Environ Health Perspect (1993) 1.06
Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res (1992) 1.02
Statistical approaches for analyzing mutational spectra: some recommendations for categorical data. Genetics (1994) 1.01
Exploratory analysis of population genetic assessment as a water quality indicator. I. Pimephales notatus. Ecotoxicol Environ Saf (1995) 1.00
Exploratory analysis of population genetic assessment as a water quality indicator. II. Campostoma anomalum. Ecotoxicol Environ Saf (1995) 1.00
The application of a multistage model that incorporates DNA damage and repair to the analysis of initiation/promotion experiments. Math Biosci (1991) 1.00
Birth and death/differentiation rates of papillomas in mouse skin. Carcinogenesis (1992) 0.99
Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect (1996) 0.96
Effects of the mechanism of receptor-mediated gene expression on the shape of the dose-response curve. Risk Anal (1993) 0.95
Design of animal carcinogenicity studies for goodness-of-fit of multistage models. Fundam Appl Toxicol (1984) 0.95
A mechanistic model of effects of dioxin on gene expression in the rat liver. Toxicol Appl Pharmacol (1993) 0.95
The exact formula for tumor incidence in the two-stage model. Risk Anal (1994) 0.95
Workshop overview. National Toxicology Program Studies: principles of dose selection and applications to mechanistic based risk assessment. Fundam Appl Toxicol (1996) 0.93
Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Toxicol Appl Pharmacol (1997) 0.92
Characterizing dose-response: I: Critical assessment of the benchmark dose concept. Risk Anal (1998) 0.89
A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol Appl Pharmacol (1996) 0.89
Risk assessment--the mother of all uncertainties. Disciplinary perspectives on uncertainty in risk assessment. Ann N Y Acad Sci (1999) 0.88
Nonlinearity of dose-response functions for carcinogenicity. Environ Health Perspect (1994) 0.88
Identification of a cardiac sodium channel insensitive to synthetic modulators. J Cardiovasc Pharmacol Ther (2001) 0.86
Induction of lung lesions in female rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Pathol (2000) 0.85
Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism. Toxicol Appl Pharmacol (1998) 0.85
A biomathematical model of particle clearance and retention in the lungs of coal miners. II. Evaluation of variability and uncertainty. Regul Toxicol Pharmacol (2001) 0.85
Two-stage models of tumor incidence for historical control animals in the National Toxicology Program's carcinogenicity experiments. J Toxicol Environ Health (1989) 0.85
Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. Toxicol Appl Pharmacol (2006) 0.85
Physiological modeling of a proposed mechanism of enzyme induction by TCDD. Toxicology (2001) 0.84
Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol Appl Pharmacol (1999) 0.84
Cell proliferation and chemical carcinogenesis: symposium overview. Environ Health Perspect (1993) 0.84
An illustration of dangers of ignoring survival differences in carcinogenic data. J Appl Toxicol (1988) 0.83
Cell proliferation and chemical carcinogenesis: a symposium overview. Mol Carcinog (1993) 0.83
Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. Toxicol Appl Pharmacol (2004) 0.82
Human cancer risk and exposure to 1,3-butadiene--a tale of mice and men. Scand J Work Environ Health (2000) 0.81
Reevaluating cancer risk estimates for short-term exposure scenarios. Toxicol Sci (2000) 0.81
A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice. Toxicol Appl Pharmacol (2001) 0.81
Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice. Carcinogenesis (1999) 0.81
Semiparametric analysis of tumor incidence rates in survival/sacrifice experiments. Biometrics (1987) 0.81
Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice. Drug Metab Dispos (1998) 0.81
Differential survivorship among allozyme genotypes of Hyalella azteca exposed to cadmium, zinc or low pH. Aquat Toxicol (2001) 0.80
Distinguishing between models of carcinogenesis: the role of clonal expansion. Fundam Appl Toxicol (1991) 0.80
Quantitative mechanistically based dose-response modeling with endocrine-active compounds. Environ Health Perspect (1999) 0.79
Replication potential of cells via the protein kinase C-MAPK pathway: application of a mathematical model. Bull Math Biol (1999) 0.79
Should the presence of carcinogens in breast milk discourage breast feeding? Regul Toxicol Pharmacol (1991) 0.79
The two-stage model of carcinogenesis: overcoming the nonidentifiability dilemma. Risk Anal (1997) 0.79
Stochastic simulation of a multistage model of carcinogenesis. Math Biosci (1996) 0.78
A note on fitting one-compartment models: non-linear least squares versus linear least squares using transformed data. J Appl Toxicol (1990) 0.78
Toxicant- and response-specific comparisons of statistical methods for estimating effective concentrations. Environ Toxicol Chem (2001) 0.78
Carcinogenicity of butadiene. Science (1992) 0.77
Hepatocarcinogenesis in female Sprague-Dawley rats following discontinuous treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci (2000) 0.77
Added risk and inverse estimation for count responses in reproductive aquatic toxicology studies. Biometrics (1998) 0.77
Calculation of the cumulative distribution function of the time to a small observable tumor. Bull Math Biol (2000) 0.77
Effects of ketanserin and DOI on spontaneous and 5-HT-evoked peristalsis of the pig ureter in vivo. Br J Pharmacol (2002) 0.77
Incorporating observability thresholds of tumors into the two-stage carcinogenesis model. Math Biosci (2000) 0.77
A mathematical model of production, distribution, and metabolism of melatonin in mammalian systems. Toxicol Appl Pharmacol (1997) 0.77
In vitro effects of bethanechol on smooth muscle preparations from abomasal fundus, corpus, and antrum of dairy cows. Res Vet Sci (2007) 0.77
A note on approximating the cumulative distribution function of the time to tumor onset in multistage models. Biometrics (1989) 0.77
A physiologically based pharmacokinetic model of p,p'-dichlorodiphenylsulfone. Toxicol Appl Pharmacol (2002) 0.76
A stem cell model for carcinogenesis. Math Biosci (1994) 0.76
The importance of biological realism in dioxin risk assessment models. Risk Anal (1994) 0.76
The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model. Fundam Appl Toxicol (1994) 0.76
Concordance of carcinogenic response between rodent species: potency dependence and potential underestimation. Risk Anal (1992) 0.75
Environment and health: 9. The science of risk assessment. CMAJ (2001) 0.75
Modeling epidemiologic studies of occupational cohorts for the quantitative assessment of carcinogenic hazards. Am J Ind Med (1995) 0.75
Eyes closed: simple, intuitive, statistically sound, and efficient methods for estimating parameters of clonal growth cancer models. Risk Anal (1998) 0.75
Stereoselective biotransformation of ketamine in equine liver and lung microsomes. J Vet Pharmacol Ther (2008) 0.75
Optimal design allocations for estimating area under curves for studies employing destructive sampling. J Pharmacokinet Biopharm (1989) 0.75
A model of effects of TCDD on expression of rat liver proteins. Prog Clin Biol Res (1994) 0.75
An evaluation of the Rai and Van Ryzin dose-response model in teratology. Risk Anal (1991) 0.75
Methodological issues of using observational human data in lung dosimetry models for particulates. Sci Total Environ (2001) 0.75
The use of data on biologically reactive intermediates in risk assessment. Adv Exp Med Biol (1996) 0.75
Time-to-tumour risk assessment for 1,3-butadiene based on exposure of mice to low doses by inhalation. IARC Sci Publ (1993) 0.75
Estimating infectivity rates and attack windows for two viruses. Math Biosci (2012) 0.75
Practicing safe modeling: GLP for biologically based mechanistic models. Environ Health Perspect (1996) 0.75
Comparing toxicologic and epidemiologic studies: methylene chloride--a case study. Risk Anal (1993) 0.75
Epidemiologic approaches to risk assessment. Inhal Toxicol (2000) 0.75
Carcinoma formation in NMRI mouse skin painting studies is a process suggesting greater than two stages. Carcinogenesis (1995) 0.75
Multistage models of carcinogenesis: an approximation for the size and number distribution of late-stage clones. Risk Anal (1994) 0.75
An evaluation of some methods for fitting dose-response models to quantal-response developmental toxicology data. Biometrics (1993) 0.75
Common themes at the workshop on uncertainty in the risk assessment of environmental and occupational hazards. Ann N Y Acad Sci (1999) 0.75
Quantitative analysis of multiple phenotype enzyme-altered foci in rat hepatocarcinogenesis experiments: the multipath/multistage model. Carcinogenesis (1995) 0.75
Biological and statistical approaches to predicting human lung cancer risk from silica. J Environ Pathol Toxicol Oncol (2001) 0.75
Type 1 error and power of the linear trend test in proportions under the National Toxicology Program's modified pathology protocol. Fundam Appl Toxicol (1986) 0.75
An index of tumorigenic potency. Biometrics (1993) 0.75
Simulating failure times when the event of interest is unobservable with emphasis on animal carcinogenicity studies. Comput Biomed Res (1987) 0.75